150 related articles for article (PubMed ID: 34905056)
41. Plasma concentrations of o,p'DDD, o,p'DDA, and o,p'DDE as predictors of tumor response to mitotane in adrenocortical carcinoma: results of a retrospective ENS@T multicenter study.
Hermsen IG; Fassnacht M; Terzolo M; Houterman S; den Hartigh J; Leboulleux S; Daffara F; Berruti A; Chadarevian R; Schlumberger M; Allolio B; Haak HR; Baudin E
J Clin Endocrinol Metab; 2011 Jun; 96(6):1844-51. PubMed ID: 21470991
[TBL] [Abstract][Full Text] [Related]
42. Assessment of serum-free cortisol levels in patients with adrenocortical carcinoma treated with mitotane: a pilot study.
Alexandraki KI; Kaltsas GA; le Roux CW; Fassnacht M; Ajodha S; Christ-Crain M; Akker SA; Drake WM; Edwards R; Allolio B; Grossman AB
Clin Endocrinol (Oxf); 2010 Mar; 72(3):305-11. PubMed ID: 19473175
[TBL] [Abstract][Full Text] [Related]
43. Benefits of Adjuvant Mitotane after Resection of Adrenocortical Carcinoma: A Systematic Review and Meta-Analysis.
Tang Y; Liu Z; Zou Z; Liang J; Lu Y; Zhu Y
Biomed Res Int; 2018; 2018():9362108. PubMed ID: 29967789
[TBL] [Abstract][Full Text] [Related]
44. Lack of long-lasting effects of mitotane adjuvant therapy in a mouse xenograft model of adrenocortical carcinoma.
Doghman M; Lalli E
Mol Cell Endocrinol; 2013 Dec; 381(1-2):66-9. PubMed ID: 23906534
[TBL] [Abstract][Full Text] [Related]
45. The long-term survival in adrenocortical carcinoma with active surgical management and use of monitored mitotane.
Wängberg B; Khorram-Manesh A; Jansson S; Nilsson B; Nilsson O; Jakobsson CE; Lindstedt S; Odén A; Ahlman H
Endocr Relat Cancer; 2010 Mar; 17(1):265-72. PubMed ID: 20026647
[TBL] [Abstract][Full Text] [Related]
46. Pregnancy in a patient with adrenal carcinoma treated with mitotane: a case report and review of literature.
Tripto-Shkolnik L; Blumenfeld Z; Bronshtein M; Salmon A; Jaffe A
J Clin Endocrinol Metab; 2013 Feb; 98(2):443-7. PubMed ID: 23275528
[TBL] [Abstract][Full Text] [Related]
47. Combination chemotherapy in advanced adrenocortical carcinoma.
Fassnacht M; Terzolo M; Allolio B; Baudin E; Haak H; Berruti A; Welin S; Schade-Brittinger C; Lacroix A; Jarzab B; Sorbye H; Torpy DJ; Stepan V; Schteingart DE; Arlt W; Kroiss M; Leboulleux S; Sperone P; Sundin A; Hermsen I; Hahner S; Willenberg HS; Tabarin A; Quinkler M; de la Fouchardière C; Schlumberger M; Mantero F; Weismann D; Beuschlein F; Gelderblom H; Wilmink H; Sender M; Edgerly M; Kenn W; Fojo T; Müller HH; Skogseid B;
N Engl J Med; 2012 Jun; 366(23):2189-97. PubMed ID: 22551107
[TBL] [Abstract][Full Text] [Related]
48. Risk of adrenocortical carcinoma in adrenal tumours greater than 8 cm.
Abdel-Aziz TE; Rajeev P; Sadler G; Weaver A; Mihai R
World J Surg; 2015 May; 39(5):1268-73. PubMed ID: 25526921
[TBL] [Abstract][Full Text] [Related]
49. Mitotane-induced dyspnoea: an unusual side effect.
Farooq AU; Amjad W; Kochar T; Adhikari S
BMJ Case Rep; 2018 Sep; 2018():. PubMed ID: 30173131
[TBL] [Abstract][Full Text] [Related]
50. Phase II evaluation of cisplatin and etoposide followed by mitotane at disease progression in patients with locally advanced or metastatic adrenocortical carcinoma: a Southwest Oncology Group Study.
Williamson SK; Lew D; Miller GJ; Balcerzak SP; Baker LH; Crawford ED
Cancer; 2000 Mar; 88(5):1159-65. PubMed ID: 10699907
[TBL] [Abstract][Full Text] [Related]
51. Recovery of adrenal function after stopping mitotane in patients with adrenocortical carcinoma.
Altieri B; Kimpel O; Megerle F; Detomas M; Chifu I; Fuss CT; Quinkler M; Kroiss M; Fassnacht M
Eur J Endocrinol; 2024 Feb; 190(2):139-150. PubMed ID: 38244214
[TBL] [Abstract][Full Text] [Related]
52. Rapid and Complete Remission of Metastatic Adrenocortical Carcinoma Persisting 10 Years After Treatment With Mitotane Monotherapy: Case Report and Review of the Literature.
El Ghorayeb N; Rondeau G; Latour M; Cohade C; Olney H; Lacroix A; Perrotte P; Sabourin A; Mazzuco TL; Bourdeau I
Medicine (Baltimore); 2016 Mar; 95(13):e3180. PubMed ID: 27043680
[TBL] [Abstract][Full Text] [Related]
53. Prognostic markers of survival after combined mitotane- and platinum-based chemotherapy in metastatic adrenocortical carcinoma.
Malandrino P; Al Ghuzlan A; Castaing M; Young J; Caillou B; Travagli JP; Elias D; de Baere T; Dromain C; Paci A; Chanson P; Schlumberger M; Leboulleux S; Baudin E
Endocr Relat Cancer; 2010 Sep; 17(3):797-807. PubMed ID: 20592067
[TBL] [Abstract][Full Text] [Related]
54. Key factors for effective mitotane therapy in children with adrenocortical carcinoma.
Kuhlen M; Mier P; Kunstreich M; Lessel L; Schneider D; Brecht I; Schewe DM; Frühwald MC; Vorwerk P; Redlich A
Endocr Relat Cancer; 2022 Sep; 29(9):545-555. PubMed ID: 35900840
[TBL] [Abstract][Full Text] [Related]
55. Objective Response and Prolonged Disease Control of Advanced Adrenocortical Carcinoma with Cabozantinib.
Kroiss M; Megerle F; Kurlbaum M; Zimmermann S; Wendler J; Jimenez C; Lapa C; Quinkler M; Scherf-Clavel O; Habra MA; Fassnacht M
J Clin Endocrinol Metab; 2020 May; 105(5):1461-8. PubMed ID: 31900481
[TBL] [Abstract][Full Text] [Related]
56. Central Hypothyroidism is Frequent During Mitotane Therapy in Adrenocortical Cancer Patients: Prevalence and Timeline.
Poirier J; Godemel S; Mourot A; Grunenwald S; Olney HJ; Le XK; Lacroix A; Caron P; Bourdeau I
J Clin Endocrinol Metab; 2023 Aug; 108(9):2336-2342. PubMed ID: 36856782
[TBL] [Abstract][Full Text] [Related]
57. Population Pharmacokinetic and Pharmacogenetic Analysis of Mitotane in Patients with Adrenocortical Carcinoma: Towards Individualized Dosing.
Yin A; Ettaieb MHT; Swen JJ; van Deun L; Kerkhofs TMA; van der Straaten RJHM; Corssmit EPM; Gelderblom H; Kerstens MN; Feelders RA; Eekhoff M; Timmers HJLM; D'Avolio A; Cusato J; Guchelaar HJ; Haak HR; Moes DJAR
Clin Pharmacokinet; 2021 Jan; 60(1):89-102. PubMed ID: 32607875
[TBL] [Abstract][Full Text] [Related]
58. Androgen serum levels in male patients with adrenocortical carcinoma given mitotane therapy: A single center retrospective longitudinal study.
Delbarba A; Cosentini D; Facondo P; Laganà M; Pezzaioli LC; Cremaschi V; Alberti A; Grisanti S; Cappelli C; Ferlin A; Berruti A
Front Endocrinol (Lausanne); 2023; 14():1128061. PubMed ID: 37077359
[TBL] [Abstract][Full Text] [Related]
59. Prospective evaluation of mitotane toxicity in adrenocortical cancer patients treated adjuvantly.
Daffara F; De Francia S; Reimondo G; Zaggia B; Aroasio E; Porpiglia F; Volante M; Termine A; Di Carlo F; Dogliotti L; Angeli A; Berruti A; Terzolo M
Endocr Relat Cancer; 2008 Dec; 15(4):1043-53. PubMed ID: 18824557
[TBL] [Abstract][Full Text] [Related]
60. Inhibition of Human Adrenocortical Cancer Cell Growth by Temozolomide in Vitro and the Role of the MGMT Gene.
Creemers SG; van Koetsveld PM; van den Dungen ES; Korpershoek E; van Kemenade FJ; Franssen GJ; de Herder WW; Feelders RA; Hofland LJ
J Clin Endocrinol Metab; 2016 Dec; 101(12):4574-4584. PubMed ID: 27603910
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
